The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 11.55 — safe zoneOK
- Earnings-manipulation signal · Beneish M 56.82 — flag raised, worth a closer lookWatch
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Keros Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- License revenue$205.4M
- Service and other revenue$38.7M
- Service revenue$38.5M
Leadership changes
From Keros Therapeutics, Inc.'s own filings, the day they're filed.
- Carl Gordon · director · departureeff. 2026-03-09
- Jasbir Seehra · Chief Executive Officer · appointmenteff. 2025-08-18
- Jean-Jacques Bienaim · Chair · appointmenteff. 2025-08-18
Latest filings
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-08-03
- 10-Q · Quarterly report2026-08-03
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-07-22
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Keros Therapeutics, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Keros Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.